CYP2C19*2 AND CYP2C19*3 polymorphism in patients diagnosed with breast cancer

Juan Manuel Pérez-Agudelo; Jhon Fredy Betancur Pérez; Carolina Osorio Solano; María Alejandra Acosta Cerquera; Paula Tatiana Uribe Echeverry

2019, Number 1

<< Back Next >>

Rev Cubana Farm 2019; 52 (1)

**CYP2C192 AND CYP2C193 polymorphism in patients diagnosed with breast cancer**

Pérez-Agudelo JM, Betancur PJF, Osorio SC, Acosta CMA, Uribe EPT

Full text

How to cite this article

Language: Spanish
References: 25
Page: 1-11
PDF size: 482.90 Kb.

ABSTRACT

Introduction: Breast cancer is the neoplasic condition with the higher prevalence in women, both in developed and developing countries. The increase of its incidence it is related with different factors as: the increase of the life expectancy, the growth of urbanization and the adoption of Western life styles. In Colombia, breast cancer represents the second most frequent neoplasm in women.
Objective: To identify the alleles for CYP2C19 * 2 and CYP2C19 * 3 in patients with breast cancer and their possible association with the pharmacotherapeutic intervention based on suppressive hormone therapy.
Methods: Observational, cross-sectional and descriptive research, in which 50 women from Caldas district with a diagnosis of breast cancer under treatment with tamoxifen participated. Prior informed consent, peripheral blood extraction was carried out, and DNA extraction was performed followed by amplification of CYP2C19*2 and CYP2C19 *3 alleles, and digestion with the SmaI and BamHI restriction enzymes.
Results: In the analyzed population, the CYP2C19*3 alleles did not show polymorphisms while the CYP2C19*2 gene’s alleles showed to be polymorphic; 42 % were characterized as wild alleles (*1/*1) and 58 % were heterozygous alleles (*1/*2).
Conclusions: CYP2C19 * 3 allele did not present polymorphisms, whereas, CYP2C19 * 2 with a high proportion of heterozygotes establishes the adequate activation of the prodrug called Tamoxifen. The genotyping of CYP2C19 has a high potential in the establishment of pharmacotherapeutic guidelines in patients with breast cancer in the studied Colombian population.

REFERENCES

Pardo-Ramos C, Cendales-Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Bogotá: Ministerio de Salud y Protección Social; 2015.
Águila R, Torres M, Rita E, Crespo-González C, Junco-Sena B, Valiente MW. Cáncer de mama, su caracterización epidemiológica. Rev Cienc Médicas Pinar Río. 2015;19(4):619-29
Angarita FA, Acuña SA. Cáncer de seno: de la epidemiología al tratamiento. Universitas. 2014;49(3):344-72
Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2014;72(2):333-8.
Shih Y-CT, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2- Year Follow-Up Study. J Clin Oncol. 2009;27(12):2007-14.
Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing. Journal of the National Comprehensive Cancer Network. 2009;7(2):203-13.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Desta Z. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin Oncol. 2005;23(36):9312-31.
Quiñones S, Rosero P, Roco A, Moreno I, Sasso J, Varela N, et al. Papel de las enzimas citocromo p450 en el metabolismo de fármacos antineoplásicos: Situación actual y perspectivas terapéuticas. Rev méd Chile. 2008;136(10):1327-35.
Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 2013;368(1612):20120431.
Zanger UM, Schwab M. Cytocrhome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeut. 2013;138:103-41.
Schaik I, Beelen K, Opdam M, Severson TM, Koornstra RHT, Vincent AD, et al. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat. 2013;139(3):649-55.
De Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet. 2015;54(8):797-810.
Uribe PT, Herrera C, Orozco C, Betancur JF. Uso alternativo del colorante GELRED en la tinción de ácidos nucleicos. Archivos de medicina. 2013;13(2):24-9.
Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PloS One. 2013;8(12):e82562.
Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol. 2003;56(3):331–3.
Hudis CA, Dickler M. Increasing Precision in Adjuvant Therapy for Breast Cancer. N Engl J Med. 2016;375(8):790-1.
Lee SJ. Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet. 2013;3(318):1-7
Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PloS One. 2013;8(12):e82562.
Scott SA, Sangkuhl K, Stein CM, Hulot J-S, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clin Pharmacol Ther. 2013;94(3):317-23.
Pérez JM, Castaño CE. Prevalencia alélica CYP2C19 en pacientes con riesgo cardiovascular de la ciudad de Manizales e historial de tratamiento con clopidogrel. Rev Médica Risaralda. 2015[acceso: 14/11/2017];21(0). Disponible en: http://revistas.utp.edu.co/index.php/revistamedica/article/view/10611
Perini JA, Vargens DD, Santana ISC, Moriguchi EH, Ribeiro-dos-Santos AKC, Tsutsumi M, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res. 2009;42(12):1179-84.
Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011;12:13.
De Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet. 2015;54(8):797-810.
Sim S, Lövrot J, Lindh JD, Bergh J, Xie H. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics. 2018;19(13):1027-37.
Van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011;12(8):1137-46.